Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LGALS8 | O00214 | 2/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | AMY2A | P04746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23704408 | 1.00 | LGALS8 (0.31) | LGALS8L3MBTL1MAPTAMY2A | |
| SCHEMBL19306157 | 1.00 | LGALS8 (0.31) | LGALS8L3MBTL1MAPTAMY2A | |
| SCHEMBL23352090 | 0.90 | AMY2A (0.32) | LGALS8L3MBTL1AMY2A | |
| SCHEMBL13728774 | 0.89 | LGALS8 (0.39) | LGALS8AMY2A | |
| SCHEMBL21517909 | 0.89 | LGALS8 (0.39) | LGALS8AMY2A | |
| SCHEMBL16687789 | 0.89 | LGALS8 (0.39) | LGALS8AMY2A | |
| SCHEMBL19317375 | 0.85 | — | — | |
| SCHEMBL17540865 | 0.81 | AMY2A (0.41) | LGALS8L3MBTL1AMY2A | |
| SCHEMBL931603 | 0.81 | LGALS8 (0.32) | LGALS8 | |
| SCHEMBL16518072 | 0.81 | LGALS8 (0.32) | LGALS8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180296507-A1 | REDOX-ACTIVATED GLYCOCONJUGATED PROCHELATORS | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2018-10-18 | — | — | US | disclosed |
| CN-105732733-A | Novel glucose-based brain-targeting prodrug with locking function | 四川大学 | 2016-07-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180296507-A1 | REDOX-ACTIVATED GLYCOCONJUGATED PROCHELATORS | SLC2A1, SLC2A2, SLC2A4 | LGALS8 249/4885L3MBTL1 2450/4885MAPT 4380/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.